Celltrion seeks FDA clearance for 240mg high-dose Zymfentra trial
AI Summary- Celltrion submitted an FDA application for a Phase 4 trial of 240mg Zymfentra.
- The study will enroll 447 Crohn's disease and ulcerative colitis patients across 55 U.S. sites.
- Zymfentra revenue reached 99.5 billion won in the first half, up 176.4% year over year.